# Lesley Fallowfield

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lesley-fallowfield/

## Facts

| Field | Value |
| --- | --- |
| Citations | 48,668 |
| Field | Cancer survivorship and care |
| h-index | 104 |
| i10-index | 305 |
| Last Known Institution | University of Sussex |
| OpenAlex ID | https://openalex.org/A5079115955 |
| ORCID iD | 0000-0003-0577-4518 |
| Works | 610 |

## Researcher papers

Showing 12 of 17.

- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer](https://scholariq.org/papers/a-randomized-trial-of-exemestane-after-two-to-three-years-of-tamoxifen-therapy/)
- [Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial](https://scholariq.org/papers/randomized-multicenter-trial-of-sentinel-node-biopsy-versus-standard-axillary/)
- [5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)](https://scholariq.org/papers/5th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-5/)
- [Ovarian cancer](https://scholariq.org/papers/ovarian-cancer/)
- [4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)](https://scholariq.org/papers/4th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-4/)
- [Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial](https://scholariq.org/papers/ovarian-cancer-screening-and-mortality-in-the-uk-collaborative-trial-of-ovarian/)
- [Communicating sad, bad, and difficult news in medicine](https://scholariq.org/papers/communicating-sad-bad-and-difficult-news-in-medicine/)
- [Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial](https://scholariq.org/papers/survival-and-safety-of-exemestane-versus-tamoxifen-after-2-3-years-tamoxifen/)
- [Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial](https://scholariq.org/papers/efficacy-of-a-cancer-research-uk-communication-skills-training-model-for/)
- [Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline](https://scholariq.org/papers/endocrine-therapy-for-hormone-receptor-positive-metastatic-breast-cancer/)
- [Addressing overtreatment of screen detected DCIS; the LORIS trial](https://scholariq.org/papers/addressing-overtreatment-of-screen-detected-dcis-the-loris-trial/)

## Researcher topics

- [Cancer survivorship and care](https://scholariq.org/topics/cancer-survivorship-and-care/)
- [Patient-Provider Communication in Healthcare](https://scholariq.org/topics/patient-provider-communication-in-healthcare/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [University of Sussex](https://scholariq.org/institutions/university-of-sussex/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.